|1.||Cannon, Christopher P: 29 articles (09/2008 - 07/2002)|
|2.||Murphy, Sabina A: 24 articles (09/2008 - 07/2002)|
|3.||DiBattiste, Peter M: 23 articles (05/2005 - 05/2002)|
|4.||Braunwald, Eugene: 19 articles (09/2008 - 07/2002)|
|5.||Valgimigli, Marco: 17 articles (04/2013 - 05/2004)|
|6.||Gibson, C Michael: 17 articles (01/2012 - 07/2002)|
|7.||van 't Hof, Arnoud W J: 16 articles (05/2012 - 05/2004)|
|8.||Campo, Gianluca: 14 articles (04/2013 - 05/2004)|
|9.||Demopoulos, Laura A: 14 articles (09/2006 - 06/2002)|
|10.||Hamm, Christian: 13 articles (12/2014 - 07/2003)|
07/01/2010 - "There was a significant reduction in the occurrence of fatal myocardial infarction (MI) (1 versus 8; p-value is 0.044) and non-fatal MI at Day 7 (1 versus 8; p-value is 0.044), and refractory ischaemia at the end of one month (14 versus 24; p-value is 0.04) and three months (25 versus 36; p-value is less than 0.01) in patients receiving tirofiban as compared to those receiving a placebo. "
01/01/2010 - "When compared with placebo, tirofiban was associated at 30 days with a significant reduction in mortality [OR = 0.68 (0.54-0.86); P = 0.001] and death or myocardial infarction (MI) [OR = 0.69 (0.58-0.81); P < 0.001]. "
03/01/2005 - "Pretreatment with tirofiban proved safe and resulted in a significantly lower corrected Thrombolysis in Myocardial Infarction frame counts (21 vs 34, P = .008) indicating improved myocardial blood flow. "
01/01/2014 - "Safety and efficacy of early administration of tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis."
08/01/2013 - "To evaluate the efficacy of upstream vs. deferred administration of tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI) on clinical outcomes. "
|2.||Acute Coronary Syndrome
09/01/2009 - "To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI). "
12/01/2011 - "[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention]."
10/01/2008 - "To investigate the efficacy of intracoronary tirofiban during primary percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS). "
04/01/2007 - "Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome."
01/01/2015 - "Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials."
03/01/2012 - "In these high-risk bleeding patients, tirofiban significantly improved after percutaneous coronary intervention (PCI) ST-segment resolution. "
01/01/2013 - "Tirofiban is more effective than conventional drugs for NR during PCI, but the potential risk of bleeding complication induced by tirofiban shouldn't be ignored during clinical practices."
10/31/2008 - "We suggest that rescue use of intra-arterial tirofiban may be effective and safe, especially in hemorrhage prone situations, due to the relatively lower dose of tirofiban compared with intravenous doses."
09/18/2015 - "The results indicated that 87 shows similar antiplatelet aggregation activity as Tirofiban to the aggregation of platelet induced by all of the four agonists, but has lower bleeding risk than Tirofiban, representing a promising lead compound for further study. "
04/01/2010 - "The Sant'ANna TIrofiban Safety study (SANTISS) is an open-label investigator-initiated single-centre registry launched to assess the combination of bleeding and access site in-hospital complications (primary end-point) in patients undergoing percutaneous coronary intervention (PCI) by femoral approach only. "
07/01/2008 - "Tirofiban is a potent and specific fib receptor antagonist, used in the treatment of unstable angina. "
02/15/2006 - "Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention."
04/01/2003 - "Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris."
09/01/1997 - "Three clinical trials, PRISM, PRISM PLUS, and RESTORE, have evaluated the safety and efficacy of tirofiban in unstable angina and in high-risk percutaneous transluminal coronary angioplasty (PTCA). "
01/01/2002 - "Tirofiban was compared to placebo after high-risk angioplasty for AMI or unstable angina. "
11/01/2009 - "After tirofiban administration, a high-level thrombus resolution was obtained, with a significant improvement in coronary flow, and a successful PCI with stenting was performed. "
01/01/2014 - "It was simple, safe and effective to perform intracoronary tirofiban administration in patients with serious thrombus burden and STEMI when undergoing emergency PCI."
04/19/2012 - "The aim of the current study was to evaluate the additional benefit of tirofiban to thrombus aspiration during primary PCI in myocardial reperfusion. "
01/01/2014 - "A total of 104 patients with serious thrombus burden and acute STEMI were randomly divided into treatment (intracoronary tirofiban administration, 56 cases) and control (48 cases) groups. "
10/01/2013 - "Thrombus aspiration combined with intracoronary tirofiban during recovery from acute MI was effective and relatively well tolerated."
|3.||Aspirin (Acetylsalicylic Acid)
|9.||Platelet Membrane Glycoprotein IIb
|1.||Angioplasty (Angioplasty, Transluminal)
|4.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)